These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 29909093)
1. The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. van Pelt LJ; Lukens MV; Testa S; Chatelain B; Douxfils J; Mullier F Thromb Res; 2018 Aug; 168():63-66. PubMed ID: 29909093 [No Abstract] [Full Text] [Related]
2. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins. Alban S; Lühn S; Schiemann S Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors. Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624 [TBL] [Abstract][Full Text] [Related]
5. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Verhoef D; Visscher KM; Vosmeer CR; Cheung KL; Reitsma PH; Geerke DP; Bos MHA Nat Commun; 2017 Sep; 8(1):528. PubMed ID: 28904343 [TBL] [Abstract][Full Text] [Related]
6. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition. Zhu Y; Lin Y; Liu X; Hu W; Wang Y Biochem Biophys Res Commun; 2017 Jan; 483(1):495-501. PubMed ID: 28007598 [TBL] [Abstract][Full Text] [Related]
7. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo. Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486 [TBL] [Abstract][Full Text] [Related]
8. Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients. Amiral J; Dunois C; Amiral C; Seghatchian J Transfus Apher Sci; 2016 Oct; 55(2):249-261. PubMed ID: 27692605 [TBL] [Abstract][Full Text] [Related]
9. Anti-Xa activity in VTE patients treated with fondaparinux. Ota S; Wada H; Mastuda A; Ogihara Y; Yamada N; Nakamura M; Ito M Clin Chim Acta; 2015 Mar; 442():22-3. PubMed ID: 25584459 [No Abstract] [Full Text] [Related]
10. Mixing factor Xa and thrombin inhibiting direct oral anticoagulants produces a synergistic prolonging effect on most clotting tests. Exner T; Ellwood L; Dangol M; Favaloro EJ Int J Lab Hematol; 2023 Aug; 45(4):603-606. PubMed ID: 36808879 [No Abstract] [Full Text] [Related]
11. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063 [TBL] [Abstract][Full Text] [Related]
12. Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives. Gao JS; Tong XP; Chang YQ; He YX; Mei YD; Tan PH; Guo JL; Liao GC; Xiao GK; Chen WM; Zhou SF; Sun PH Drug Des Devel Ther; 2015; 9():1743-59. PubMed ID: 25848211 [TBL] [Abstract][Full Text] [Related]
13. [Effect on low-molecular-weight heparin obtained using a chitinolytic complex on the anticoagulant activity of plasma in rabbits and rats]. Drozd NN; Tolstenkov AS; Makarov VA; Miftakhova NT; Bannikova GE; Sukhanova PP; Varlamov VP; Vikhoreva GE Eksp Klin Farmakol; 2007; 70(2):40-4. PubMed ID: 17523450 [TBL] [Abstract][Full Text] [Related]
14. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa. Thakur R; Kumar A; Bose B; Panda D; Saikia D; Chattopadhyay P; Mukherjee AK Biochimie; 2014 Oct; 105():149-58. PubMed ID: 25038567 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity. Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110 [TBL] [Abstract][Full Text] [Related]
16. Urgent Need to Measure Effects of Direct Oral Anticoagulants. Weitz JI; Eikelboom JW Circulation; 2016 Jul; 134(3):186-8. PubMed ID: 27436877 [No Abstract] [Full Text] [Related]
18. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946 [TBL] [Abstract][Full Text] [Related]
19. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632 [TBL] [Abstract][Full Text] [Related]
20. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study. Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V Nephron; 2017; 137(3):205-211. PubMed ID: 28817831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]